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The increasing burden of respiratory diseases caused by microbial infections poses an immense threat
to global health. This review focuses on the various types of biofilms that affect the respiratory system
and cause pulmonary infections, specifically bacterial biofilms. The article also sheds light on the cur-
rent strategies employed for the treatment of such pulmonary infection-causing biofilms. The potential
of nanocarriers as an effective treatment modality for pulmonary infections is discussed, along with the
challenges faced during treatment and the measures that may be implemented to overcome these. Under-
standing the primary approaches of treatment against biofilm infection and applications of drug-delivery
systems that employ nanoparticle-based approaches in the disruption of biofilms are of utmost interest
which may guide scientists to explore the vistas of biofilm research while determining suitable treatment
modalities for pulmonary respiratory infections.
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Biofilms are defined as colonies of microorganisms surrounded by self-secreted matrices that grow on living or inert
surfaces (Figure 1). Generally, biofilms are deposited on abiotic and biotic surfaces. For instance, they can grow on
rocks (abiotic), plants, fungi or a human host (biotic). Biofilms are one of the primary causes of lower respiratory
tract infections. These infections may be particularly complicated to treat and are one of the foremost causes of
death in developing countries worldwide [1]. Patients with chronic respiratory diseases are at particularly a higher
risk of such infections and are one of the principal causes of morbidity and mortality in this group [2]. In addition
to the high mortality and morbidity rates, respiratory infections can also impact economies because they can lead
to increased treatment costs [3].
The treatment of respiratory infections is challenging because the infections may possess multidrug-resistance,
and the microbes may reside deep inside the airways. Delivery of drugs to such deeper parts of the airway
system remains a major milestone to be accomplished. Despite the efforts of oral or parenteral administration, the
concentration of drug that reaches the site of the problem is small and therefore, high doses of the active drug are
needed to maintain the level of drug greater than their minimum inhibitory concentrations (MIC) at the site of
infection [4]. Unfortunately, administration of high doses of certain drugs may result in increased toxicity and can
even lead to acute neurotoxicity and nephrotoxicity in the patients [5].
Controlled discharge of drugs or antibiotics to the respiratory tract might be an effective solution to this problem
because discharge of target drugs or antibiotics directly at the point of infection would allow a higher concentration
of drug to reach the targeted biofilm with low systemic exposure [6]. Such a result was seen in a pharmacokinetic
study that involved nebulization of the drug colistin methanesulfonate (2 million IU) in cystic fibrosis (CF) patients.
The findings revealed that nebulization allowed high concentrations of the drug to be accumulated in the sputum
(Cmax 6 mg/I), which could be maintained above MIC90 for up to 12 h with negligible systemic drug exposure
(Cmax <0.3 mg/I) [7].
Research in biofilms with respect to respiratory diseases has not been explored fully and therefore requires attention
to maximize the effectiveness of the drugs in use and to improve the treatment methods and strategies available.
This review focuses on the various treatment approaches, such as nanocarriers, systemic therapy and inhaled
formulations, that can be used to tackle the biofilms causing respiratory infections. The approaches are discussed
in detail with attention to their potential benefits and drawbacks along with possible future directions.
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Figure 1. Schematic representation of cystic fibrosis lung epithelial cells. The epithelial cells of a cystic fibrosis lung
are covered by a thick, sticky mucus including bacterial biofilms, leading to a block of cellular activities and breathing
problems.
Biofilms: formation, multidrug-resistant properties & prevention
Intensive studies have been conducted in the past 2 decades to investigate microbial development in biofilms,
especially, in biofilms that are found in the natural aquatic system predominantly attached to the surface of
micro-aggregates or macro-aggregates.
Biofilm development and maturation have been demonstrated and observed in a variety of bacterial species,
including Escherichia coli, Pseudomonas aeruginosa, and Vibrio cholera [8–10]. In such studies, experiments were
conducted using a genetic screen where randomly assorted transposon mutants were allowed to mature in a 96-well
plate [11]. The findings of the studies show that the bacterial colonies primarily employ either their flagellum or type
IV pili for movement along surfaces in a collective motion until they interact with other bacteria, resulting in the
formation of small colonies, where they eventually expand and mature [8]. The production of exopolysaccharides
(EPS) helps the bacteria to become more stabilized [9]. Studies have also revealed that wild-type V. cholera has a
specialized structure that provides a greater advantage to the biofilms in providing them the ability to form colonies
on the surface. It is believed that the rate of adherence might be the key factor in obtaining a place to reside in the
microbial colony.
Biofilms may constitute either a sole species of microbe or several microbial species. Biofilms of a single species
are those generally found on the exteriors of the medical implants and in a wide range of infections in humans [12].
One of the key areas of research today involves single species biofilms that are capable of causing various respiratory
infections.
Biofilms incorporate an assemblage of microorganisms (bacteria or fungi) that are integrated into a unit containing
EPS, proteins and nucleic acids. Bacteria or fungi that can form biofilms are possibly morphic and can germinate
on surfaces such as medical devices, endotracheal tubes and tracheostomy tubes [13,14]. It has been observed that
biofilms are dependent on the fabricated material of such devices [15]. Biofilms cause serious diseases and are a
cause of worry for patients with severe respiratory diseases like CF and chronic obstructive pulmonary disease
(COPD) [16].
Multidrug-resistant properties
The multidrug-resistant properties of biofilms against antimicrobial agents may be due to several factors that are
discussed here in brief. One of the main reasons is the failure of antimicrobial drugs to penetrate the biofilm barrier.
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This also poses a challenge to drug delivery. A commonly found and used disinfectant, chlorine, was reportedly used
against Klebsiella pneumoniae and P. aeruginosa biofilms. The observations were measured with a chlorine-detecting
microelectrode. The results showed that not even >20% of chlorine reached the bulk media’s concentration [17].
The EPS matrix may also play a key role, which may contribute toward the delay in the penetration of antimicrobial
drugs. However, EPS is not the only factor that contributes to the multiresistant nature of the biofilms. There are
other multiple mechanisms such as slow growth rate, stress response and heterogeneity.
The bacterial cell culture shows a period of slow or no growth during limited supply of nutrients. This transition to
slow or no growth is suggested to be one of the physiological mechanisms that may lead to antibiotic resistance [18].
This characteristic feature is usually seen in mature biofilms [18,19]. This phenomenon was also reported in P.
aeruginosa, E. coli and Staphylococcus epidermidis biofilms under limited growth conditions by Ciofu et al. [20]. A
generalized observation was made that the effect of either tobramycin or ciprofloxacin had increased along the
growth rate in both planktonic and biofilm cells. Therefore, it was suggested that the slow growth rate of biofilm
cells was a protective mechanism against antimicrobial agents.
Lastly, heterogeneity contributes to the resistance against antimicrobial agents. The activity of K. pneumoniae
biofilm, when treated with monochloramine, showed that the biofilm cells that were closest to the biofilm-bulk-
liquid interface perished first [21]. The study further revealed that the activity of antimicrobial agents may vary
depending on the location of cells inside a biofilm.
Prevention of biofilm
Biofilm-associated infections occur frequently through skin-habitant bacterial organisms such as Staphylococcus
spp. and opportunistic fungi such as Candida spp., which are seen in immunocompromised patients. Biofilms have
the ability to grow on abiotic surfaces, which may serve as a virulence factor for microbial biofilms [22].
Therefore, strategies to prevent these infections focus on surface coating with antimicrobials and antiseptics.
This would also ensure no microbial adhesion and prevents biofilm formation. To combat the surface adhering
biofilm formation, the development of novel biomaterials such as metal nanoparticles (NPs) with surfaces modified
to alter the biophysical cell–surface interaction are favored because this prevents growth of biofilm.
Another approach to prevent biofilm formation focuses on disrupting the signaling pathways of bacterial cell
that coordinate with the genes responsible for biofilm development. For instance, the (p)ppGpp, cyclic-di-GMP
inhibitors and quorum sensing (QS) signaling have shown positive results in the prevention of biofilm formation
and could also potentially lead to novel therapeutic strategies [23].
Various types of biofilms in respiratory infection
Biofilms exhibit taxonomic diversity in many microbes, such as bacteria and fungi that cause infections in the
respiratory system. Some major biofilm infection organisms include Staphylococcus aureus and coagulase-negative
Staphylococcus spp., P. aeruginosa, Candida spp. and Aspergillus fumigatus. P. aeruginosa and A. fumigatus are mainly
associated with pulmonary disease, which are further discussed. There are researchers considering Mycobacterium
abscessus and Haemophilus influenzae as a potential pathogen for biofilm formation.
H. influenzae has been reported to possess the ability to express neuraminidases that cleave α2,3-linked sialic
acids from glycoconjugates. Neuraminidases (sialidases) are generated to adhere to the host cells by various kinds
of mucosal pathogens as seen in Streptococcus pneumoniae in the airway and V. cholerae in the gut [24]. The function
of neuraminidase is firmly established in influenza pathogenesis, whereby it helps in designing a treatment method
against it. However, the role of bacterial neuraminidase in the pathogenesis of disease is not fully understood yet. P.
aeruginosa comes from neuraminidase-secreting species that colonize the highly siaylated discharge and the surface
of upper respiratory tract [25]. The aforementioned neuraminidase secreting species may bind to the asialylated
glycolipids produced by neuraminidase action. However, this species shows varying metabolic activity or differs in
infusing sialic acid to its surface structures [26]. Therefore, it is highly possible that bacterial neuraminidase engages
with both microbic and eukaryotic glycoconjugates [25].
Mycobacterium spp. have also demonstrated their ability to form biofilm, most notably Mycobacterium tuberculosis,
which assembles itself into a highly organized matrix-encapsulated biofilm complex under favorable conditions [27].
Other nontuberculosis mycobacteria (NTM), Mycobacterium avium complex (MAC), also the fast-growing My-
cobacterium abscessus complex (MABSC), were observed to grow biofilms in vitro and environmental reservoirs [28].
MABSC has emerged as a threat to CF patients who suffer from it at an early age and deteriorate clinically as
the consistent infection results in tissue damage and inflammation [28,29]. There is a lack of direct evidence that
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suggests that MABSC is responsible for pulmonary biofilm infection, but indirect evidence supports this claim.
Laboratory and environment cultures have observed the growth of biofilm by NTM. The sputum of NTM patients
has also shown biofilm like aggregates in the acid-fast smears of sputum. Mycobacterium ulcerans is responsible for
chronic ulcers. The microbe lives in a tropical environment and is also a member of NTM, which indicates biofilm
infection [29]. Biofilm infections are found on surfaces but also penetrate deep into tissues as previously shown
in chronic wounds [30]. Similarly, MABSC might be capable of forming biofilm infections in the human lungs.
Biofilm growth could also explain the failure of therapeutics in MABSC infection and its susceptibility testing. A
study indicated two possible explanations. First, the diffusion of antibiotics was inhibited by the biofilm due to the
presence of an antibiotic concentration gradient across the biofilm aggregates leaving the bacteria viable [31]. The
second explanation suggests that it might be due to the heterogeneity of metabolic state present in a biofilm that
is able to shield the dormant bacteria and also allow for an adaptive evolution of the consistent bacteria [32]. The
MABSC biofilm infection needs more research and requires discovering more in-depth evidence that could also
lead to the discovery of more biofilm-disrupting agents.
Another prominent biofilm forming pathogen is A. fumigatus, which is responsible for causing severe pulmonary
infections. A. fumigatus is a ubiquitous filamentous fungus whose pathogenesis is beginning to emerge. This has
helped scientists to understand the importance of biofilm formation during an infection. A. fumigatus is known
to invade the respiratory systems of immunocompromised patients. The organism also inhabits the airways of
CF patients and patients suffering from other chronic pulmonary diseases. The results of histopathologic studies
conducted on human tissues and animal models of invasive chronic pulmonary infection have revealed that A.
fumigatus grows as an aggregation of hyphae within an extracellular matrix embedded as seen in a biofilm [2,33].
Experimental studies have shown that the biofilms have contributed to the virulence of this fungal species by
promoting enhanced adherence to the host cell [34]. In addition, it may increase resistance to antifungal agents
and host immune system. The biofilm formation by A. fumigatus in pulmonary diseases has resulted in a higher
failure rate of antifungal therapies in the treatment of invasive aspergillosis. Limited studies have uncovered the full
potential of A. fumigatus infection, which warrants more in-depth preclinical studies to understand the invasive
nature of the organism and its long-term consequences.
Diagnosis of biofilms
Biofilms do not have definitive diagnostic markers. This makes their recognition and diagnosis difficult. Biofilms
are classified on the basis of a combination of microbial groups, clinical and microscopic features including both
localized and persistent infections, or direct examination of infected tissues to detect microbial biofilms [35]. Biofilm
growth can also hinder the microbiological diagnosis because the microbes could not be recovered for culture as
that would cause physical disruption of surface attached biofilms.
Moreover, the in vitro antimicrobial susceptibility test has restricted percentage value in anticipating the activity
against biofilm infection. Although the antimicrobial susceptibility assay tests are somewhat useful when tested
for microbes in the planktonic state. With constant change and improvement in technology the antimicrobial
susceptibility test assay for biofilms have been made available. However, they still are not as reliable for predicting
microbiological or clinical outcomes when assessed in patients with CF infected with P. aeruginosa [36]. Although
there have been some developments for bacterial biofilms, there have been limited advancements in the area of
fungal antimicrobial susceptibility testing.
Challenges in biofilm treatment
The conventional antibiofilm drugs used in treatment strategies to date have restricted therapeutic activity against
biofilm infection.
There exist several challenges reported in the treatment methods, which include the following: identification of
a suitable antimicrobial compound, selection of a suitable drug-delivery device and optimizing the formulation for
efficient target drug delivery, especially in the sinuses and nasal cavity [37].
One of the strategies involved the use of a powder, which comprises amorphous colistin and crystalline rifapentine
with an extended antimicrobial activity against planktonic cells and P. aeruginosa biofilm employed for respiratory
infections [38]. In another study, amphibian AMP esculentin, which was employed as a new antibiotic formulation,
demonstrated significant effects in controlling the growth of P. aeruginosa in sepsis and pulmonary infections [39].
This may be potentially employed as a drug to disrupt the biofilms. The findings indicate that esculentin prolonged
the survival of animals both in sepsis and during pulmonary infections.
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Table 1. Major inhaled formulation against biofilm infection.
Serial number Biofilm-associated infection Major organism Target drug
1 Cystic fibrosis Pseudomonas aeruginosa Aztereonam
2 Pulmonary infection/disease Aspergillus fumigatus Alginate combined with apolytene antifungal
3 Nosocomial Staphylococcus epidemidis Cefazolin and vancomycin, gentamicin neutralized
with rifampicin
Several recent research advancements have suggested the successful modification and utilization of antimicrobial
transport mechanisms that are reported to be effective against several important microbes that reside in the biofilms.
Moreover, diverse NP-drug delivery and photodynamic approaches have been reported to effectively target and
disrupt biofilms by forming potentially lethal reactive oxygen species [40,41]. It is well known that photodynamic
modifications seem relatively common in microbes observed in the oral cavity and skin [41].
Antimicrobial tolerance of biofilms in vitro & in vivo
Tolerance in vitro
The antimicrobial tolerance of biofilms is believed to be linked to the growth mode of the biofilm. If the bacteria
have a planktonic culture, it will exhibit susceptibility to antimicrobial activities [18]. Tolerance in a biosystem
is multifactorial and is fundamentally different from antimicrobial resistance. It is rather attributed to restricted
penetration of antibiotics, limited growth, low oxygen levels, expression of biofilm-specific genes and presence of
persisters.
Restricted penetration
As discussed in the preceding sections, biofilms restrict the entry of antimicrobial agents and do not permit the
diffusion of drugs. The restricted penetration may occur when the antibiotics bind to the components of the biofilm
matrix or bacterial membrane, such as the extracellular DNA [19,42,43].
Differential physiological activity
Differential physiological activity of microbes in biofilm is another cause of concern in antimicrobial tolerance.
The metabolic activity is high on the outer regions and low in the inner regions of biofilms. This is due to the
limited oxygen and nutrient penetration as seen in P. aeruginosa [20].
Differential expression of specific genes in biofilms
Biofilms can show that a specific expression of genes may also contribute to a specific tolerance mechanism. For
instance, ndvB gene (PA14) in P. aeruginosa encodes for an enzyme that synthesizes periplasmic glucans binds to
tobramycin. This results in the prevention of cell death by isolating the antibiotic.
Persister cells
Persister cells are considered to be an outcome of the bacterial differentiation into a dormant stage. They can
decrease the metabolic rate, which evidently enables them to escape the effect of antibiotics even to those that kill
nongrowing cells [44,45].
Tolerance in vivo
The sputum obtained from patients with CF and chronic P. aeruginosa infection contains polymorphonuclear
leukocytes that get assembled at the site of biofilm infection and intake the oxygen, thereby creating an anaerobic
condition, and limiting bacterial growth [46]. In vitro models explain the restricted growth in the deeper layer
within a biofilm, but in such models, the biofilm itself may be located in the oxygen-deprived areas as a result
of polymorphonulcear leucocytes (PMN) inflammation or physiological conditions. The CF sputum and sinus
secretion of CF patients were also seen reporting lower oxygen tensions during biofilm infections [46,47].
Current treatment methods
Antibiotic treatment (high concentrations) administered through a topical route
Topical administration allows the delivery of antibiotics at a high local concentration directly to the target site
effectively avoiding side effects and undetectable serum concentrations. In one study, nebulized tobramycin was
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found to be 1200 mg/l in the sputum of the patient when only 1 mg/l was found in the serum concentration [42].
The current antibiotic regimen used in biofilm-originated lung infection in CF is as follows:
a) Tobramycin (300 mg) through inhalation;
b) Aztreonam (75 mg) through inhalation;
c) Ciprofloxacin (65 mg) through inhalation;
d) Levofloxacin (240 mg) through inhalation.
The antibiotics that are employed in biofilm-caused lung infection in non-CF bronchiectasis are as follows:
a) Colistin (1 MU) through inhalation;
b) Tobramycin (300 mg) through inhalation;
c) Ciprofloxacin (32.5 mg) through inhalation.
The nebulized antibiotic administration of antibiotics through inhalation have shown a marked improvement in
pulmonary symptoms and have minimized the bacterial load in the sputum. The formulations were also reported
to be well tolerated [48].
Combined & sequential antimicrobial therapies
Antimicrobial drugs are used in combination, especially in patients with CF [49]. This may be primarily done to
prevent the maturation and multiplication of multidrug-resistant biofilms. Biofilms are capable of having varied
structural functions and different metabolic states. Therefore, combining ciprofloxacin, which attacks metabolically
active layers, and colistin, which disrupts and kills the biofilm cells during low or inactive metabolic state, may
render high therapeutic efficiency [50]. Several in vivo and in vitro studies have reported combinations that have
been proved to be efficient in the treatment of biofilm-driven infections [50,51].
Inhaled antimicrobial formulations: treatment of biofilm-induced respiratory infections
Respiratory infections due to biofilms pose a serious adverse health scenario globally. Bacterial and fungal biofilm-
infection agents seem to play a significant role in causing respiratory illnesses today [2,52]. The need to develop
inhaled antimicrobial formulations has become urgent because higher doses of systemic therapies have the potential
for harmful effects. Inhaled drug formulations both for the treatment and prevention of respiratory infections
have become momentous. Recent advancements have encouraged such inhaled formulations for medical therapies.
Drug formulations not only target the primary infected sites but also shrink the risk of toxicity to a significant
level compared with drugs in systemic therapy. In addition, they also have become a major convenience to work
with clinically. The inhaled-drug formulations, as mentioned in Table 1, for the treatment of infections can be
classified on the basis of biofilm-led infections. For biofilms of bacterial, viral and fungal origin, the inhaled drug
formulations are inhaled antibiotics and inhaled antifungal agents.
Inhaled antibiotics
Inhaled antibiotics or antibacterial agents are used against bacterial-biofilm infections [53]. These antibiotics may
be approved for the treatment against CF and similar conditions. These may also be employed for off-label use
in non-CF bronchitis hyperventilation-associated pneumonia (VAP) [54]. Using these inhaled antibiotics not only
minimizes systemic exposure but also delivers a higher concentrated dosage to the respiratory tract [55]. Three of
the approved antibiotics are mentioned in Table 2
Inhaled anti-fungal agents
In addition to bacterial and viral biofilm infections, fungal biofilm infections caused by Aspergillus in the respiratory
tract are also one of the major causes of casualties. This usually results from the inhalation of fungal spores.
Patients who are already suffering from HIV-AIDS, cancer or organ transplantation are more susceptible to
fungal respiratory infections. The global morbidity and mortality rates caused by fungal biofilms are 40–90% [56].
Antifungal formulations are hence important because they not only provide a better alternative against systemic
administration of antifungal agents but also considerably reduce systemic toxicity. There are only a handful of
inhaled antifungal drugs (Table 2).
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QS inhibitors & anti-QS peptides to control biofilm infection
A recent analysis used synthetic molecules to inhibit P. aeruginosa QS receptors, LasR and RhIR [57]. Meta-bromo-
thiolactone used in the study depicted a significant inhibition of production of pyocyanin, a virulence factor and
thus prevented biofilm formation [58]. A combination of QS inhibitor FS3 and daptomycin has been used against
prosthesis biofilm in a rat model of staphylococcal vascular graft infection [59]. The use of FS3 and doptomycin
together was successful in displaying a synergistic efficacy compared with a single mode of treatment.
RNA-III inhibiting peptide was used in a study to restrain staphylococcal TRAP/agr systems and to reduce
biofilm infection in vivo. The findings point to the importance of quorum sensing in biofilm infection in the host.
The use of RNA-III peptide in rats to inhibit methicillin-resistant S. aureus graft infections, suggests that RNA-III
peptide could possibly be an antibiofilm agent [60].
Antagonists of diguanylate cyclase
Diguanylate cyclase (DGC) antagonists were found to demonstrate impairments on P. aeruginosa and Acinetobacter
baumannii [61]. Ebselen and ebselen oxide are inhibitors of c-di-GMP through inhibition of DGC’s limited c-di-
GMP in regulation of P. aeruginosa biofilm [62].
Bacteriophage therapies
Bacteriophage therapy for bacterial infections has been used in practice for a long time. The development of
multiresistant bacteria and antibiotic resistance has drawn attention to bacteriophage therapy [63]. Bacteriophages
are able to infect and kill antibiotic sensitive and resistant bacteria.
NP drug-delivery formulations
The currently available antibiotic-delivery systems have failed to eliminate biofilm-protected bacteria. Therefore,
there is an urgent need for novel therapeutic approaches, which may effectively target the site of action with minimal
side effects and low toxicity. NPs may play a key role to overcome this problem. Several nanoparticles such as PLGA
nanoparticles, liposome nanoparticles and chitosan NPs are currently found to be beneficial. The process of biofilm
formation and its action of NPs is shown in Figure 2.
Continued interest in NPs as a diagnostic, treatment and drug-delivery tool has been attributed to their
adaptability. In the case of biofilm-induced respiratory diseases and infection, nanotechnology serves as potential
therapeutic mode to ameliorate concerns and barriers that make biofilms difficult to treat. These include the poor
antibiotic penetration and nonspecificity of other administration methods. NP-based treatments includes the use
of NPs exclusively or in combined therapies.
Successful delivery strategies have employed lipid and polymeric NP-based formulations such as liposome and
cyclodextrins, respectively. Furthermore, inorganic carriers – namely, metal NP such as silver NPs – have shown
innate antimicrobial properties. The current NP-based drug-delivery systems is summarized in Table 3.
Lipid-delivery systems
Liposomes
A liposome is a simple structured NP that comprises of a spherical shape and has a lipid bilayer comprising of
phospholipids along with sterols, glycolipids, membrane proteins and hydrophilic polymers [66]. The principal
application of liposome NP-based formulations is target-specific delivery, which can encapsulate hydrophilic and
hydrophobic drug material [67]. This would allow the liposomes to be used in a diverse range of pharmaceutical
Table 2. Major pathogens causing biofilm infection and the drugs in use.
Inhaled formulations Biofilm pathogen
1. Inhaled antibiotics
a) Streptomycin Staphylococcus spp. and Pseudomonas aeruginosa
b) Aztreonam P. aeruginosa, Acinetobacter baumannii and Stenitrophomonas maltophilia
c) Colistin Pseudomonas, Acinetobacter, Klebsiella and Enterobacter
2. Inhaled antifungals
a) Pentamidine Pneumocystis carinii
b) Amphotericin B Aspergillus fumigatus
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Figure 2. Diagrammatic representation of the potential mechanisms of nanoparticles against biofilm and the
treatment of cystic fibrosis lung cells.
applications. Liposome encapsulation also exhibits potential properties of NPs in a restrained-release delivery
mechanism that forms an efficient method of drug delivery [68].
A variety of liposome-based NPs have been formulated for delivering potential antimicrobial drugs to the
biofilms and biofilm-related microbes. Various studies have revealed the applications of NPs in the drug delivery
for biofilm-associated infections. Furthermore, Scriboni et al. reported the interactions of liposome-based NPs
and some modified liposomes in an in vitro of S. aureus biofilm [69]. Streptococcus salivarius and Streptococcus
sanguis were studied by Robinson et al. in 2001 to observe the variations in absorption between anionic and
cationic liposomes in oral biofilms [70]. In the preceding studies reported on biofilms, the emphasis was on the
association between the composition of liposomal-NPs, adhesion behavior and the particularized makeup of the
biofilms. Adsorption to the biofilm is characteristic to liposomes. The varying compositions of cationic liposomes
such as dimyristoyl phosphatidylcholine, cholesterol and dimethyl dioctadecyl ammonium bromide in the ratio
of 78.6:23.2:0 to 58.5:23.0:18.5 molar ratio, and anionic liposomes (made of dimethyl dioctadecyl liposome and
phosphatidylinositol in 82.5:17.5 molar ratio) show the principal differences in the adsorption behavior with
varying compositions. In addition, the significance of electrostatic interactions is studied through the delivery of
antimicrobial agents such as nitric oxide. The interactions of cationic and anionic liposomes differ considerably.
For a cationic liposome, the bacterial interactions are directed by Van der Waals (electrostatic interaction) forces,
whereas, the adsorption of anionic liposomes onto a biofilm is an outcome of an equilibrium between attractive
hydroxy (OH) interactions and repulsive electrostatic (Van der Waals) forces associated with H-bonding. The
results of antimicrobial efficacy studies show that there are no accumulative outcomes associated with the usage of
antimicrobial-liposome particles. However, antimicrobials may damage the action of zinc citrate particles, although
the benefit of using the solid supported liposomal system gives an increased stability to the drug encapsulated
liposomes. P. aeruginosa biofilm have been primarily seen in CF, and a range of formulations with liposome drug
delivery in vitro have been developed to address this health problem [71].
Solid lipid NPs
Solid lipid NPs (SLN) are made up from solidified lipids, such as triglycerides, fatty acids, waxes and emulsifiers
that include lecithin, poloxamers, bile salts and water. SLNs are submicron dispersions of the solidified lipids into
a liquid media. SLNs are utilized for the delivery of hydrophilic and lipophilic antibiotics along with some minute
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Table 3. Nanoparticle drug-delivery systems.
NPs Mode of preparation Size (nm) Applications Ref.
Lipid-delivery system 1. Liposomes Thin film rehydration method 50–1000 Widely used for the delivery of antimicrobials to biofilms
and biofilm-associated microorganisms
2. SLNs Lipid film hydration method 80–300 SLN formulations of antimicrobial agents is primarily
used to target biofilm-forming microorganisms instead
of mature biofilms themselves
3. Microemulsions Water-in-oil or oil-in-water
microemulsions
10–300 Certain tendencies of microemulsions
(e.g., thermodynamic stability, ability to reduce toxicity
of encapsulated materials and hydrophilic, hydrophobic,
amphiphilic drug solubilizing capacity) make them
amenable for controlled release of antimicrobial delivery





1. Gold Chemical synthesis 1–150 It can provide stable, nontoxic, biocompatible delivery
vehicles for various therapeutic molecules
2. Silica Sol-gel process 200 Biomedical applications include drug delivery and
theranostics
3. Silver Evaporation–condensation or
electrical irradiation
1–100 Important in the treatment of biofilm-forming
microorganisms due to its antimicrobial property, which
includes effects against Gram-positive and
Gram-negative bacteria as well as fungi and protozoa
Pulmonary infection/disease
4. Zinc Prepared by the sol-gel method,
electrochemical depositions,
ultrasound and other processes
30 Due to its antimicrobial activity, it acts against a range of
oral pathogens, Gram-positive and Gram-negative
bacteria and fungal microorganisms; along with zinc




1. PLGA Emulsion evaporation or
emulsion diffusion
10–1000 Applications include drug delivery and diagnosis in
cardiovascular disease, cancer, vaccine and tissue
engineering
2. Dendrimers Divergent growth method 1–10 Applications include transdermal, oral, ocular and
pulmonary as well as targeted and/or controlled release
3. Cyclodextrins Coprecipitation method 80–125 Mainly works as solubilizers for compounds with weak
water solubility
[65]
NP: Nanoparticle; SLN: Solid liquid nanoparticle.
chemical bodies including peptides and proteins [72]. SLNs are slightly toxic and biocompatible. They lack any
organic solvent residues. SLNs are used to target the biofilm-developing microbes rather than developed biofilms.
Microemulsions
Microemulsions are essentially two non-miscible fluids that are composed of water, oil and a surfactant or co-
surfactant component that is transparent and thermodynamically stable [73]. Microemulsions are classified into
mainly three types, primarily based on the structure assumed by the surfactant component. The three chief
categories are oil-in-water (o/w), in which the volume of the oil is lower; one in which the volume of water is
less than that of oil, or a water-in-oil (w/o) mixture; and a bicontinuous structure that varies from an o/w to
a w/o microsystem. The o/w and w/o microemulsions are made of distinct droplets encircled by a stabilizing
layer of surfactant and scattered in an uninterrupted stage [74]. A microemulsion loaded with curcumin was used
against planktonic Streptococcus mutans, Lactobacillus casei, Actinomyces viscosus and Candida albicans. The findings
showed that the microemulsion formulation was superior in yielding more promising results against microorganisms
compared with other methods [75]. Microemulsion and nanoemulsion reportedly possess the ability to inhibit the
growth of S. aureus NCTC 1803, Streptococcus typhimurium PSB 367, Listeria monocytogenes, P. aeruginosa and E. coli
O157:H7 biofilms [75,76]. Microemulsion has also displayed a greater antimicrobial activity against P. aeruginosa. The
use of microemulsions is not limited to acting as a drug carrier; some studies reveal that the microemulsions include
components that can be used directly against microbial biofilms and show antimicrobial properties. Thermodynamic
consistency gives microemulsions the capability to lower the toxic levels of enclosed material. They may deliver
hydrophilic, hydrophobic and amphiphilic drugs and have demonstrated controlled release in antimicrobial delivery
used for the transfer, topical, ocular and parenteral administration [77,78]. Although the advantages are great, they
may also have a few drawbacks, which mainly include the presence of cosolvents like ethanol and surfactants like
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polysorbates, which have led to increased toxicity [79]. These events are reported more often in cases where repeated
dosages of drugs is needed.
Polymeric-delivery systems
PLGA
PLGA NPs are widely used in medical applications and the pharmaceutical industry due to their wide range
of applications, such as slow rate of drug release, biomaterials and scaffolds for tissue engineering and medical
devices [80,81]. For instance, microspheres are used for a contained and discharged drug-delivery system due to the
wide range of their manufacturing of polymers such as poly(lactic acid), poly(glycolic acid) (PLGA), poly(lactic-
co-glycolic acid) and poly(caprolactone) [80].
NPs are usually loaded with active drugs to accomplish a therapeutic activity. In a review, it was shown that
several functional groups related to the polymers exhibited antimicrobial activity [82]. Polymeric formulations have
been broadly used for the transfer of antimicrobial drugs to the biofilm and biofilm-developing microbes.
Cheow and Hadinoto (2012) discussed the development of rhamnolipid-triggered release from lipid-polymer hy-
brid NPs, and these rhamnolipids were expressed in P. aeruginosa biofilms and other pulmonary-related biofilms [83].
NPs were prepared with a PLGA core surrounded by a lipid coat (PC). The nanoparticles were then enclosed in the
fluoroquinolone antibiotics from categories I and IV of the Biopharmaceutical Classification System (BCS). The
solubility and the capacity to permeate through intestinal membrane of drugs are classified according to the BCS
system [84]. The BCS system classifies the drugs based on the following properties:
1. Category I drugs include levofloxacin and ofloxacin; characteristics: high solvability and high permeability;
2. Category IV drugs include ciprofloxacin; characteristics: low solvability and low permeability.
The category I drugs are freely released from the NPs with or without triggering the agents (i.e., rhamnolipid
or Triton X-100). This has demonstrated that NPs are not affected by the lipid coat. To encapsulate category
IV drugs into the lipid-polymer NPs, two contrasting PLGA coats were studied: PC/stearylamine (SA) or the
polyvinyl alcohol. Only 5% of the drug was deposited inside the polymeric core. The discharge of ciprofloxacin
from PLGA-PC/SA was 15% (w/w) after 24 h with or without the triggering agents. The PVA NPs showed an
increase in the release to ∼25% (w/w) in the absence of triggering agents. As observed in the study, the findings
clearly state that the lipid-based coat PC/SA does not directly involve in inhibiting the release of category IV drugs
– namely, ciprofloxacin from the core of PLGA NPs. This may be due to the reduced initial drug encapsulation and
related lower concentration gradient. A category I drug, levofloxacin, was found to be effective against P. aeruginosa
biofilm and planktonic cells, showing significant antibacterial activity [85].
PLGA NPs could also be altered to furnish a pH-controlled discharge of antibiotics or drugs like gentamicin
sulfate when secured with titanium [86,87]. To achieve a pH-controlled delivery form of NPs, the following procedure
was adopted. Ring-opening copolymerization of norbornene was performed with α-ω-functionalized poly(ethylene
oxide) macromers. The α-functionalization of the macromonomer was then achieved with the norbornene groups.
ω-functionalization with the antibiotic, gentamicin sulfate and carboxylic acid group allows the grafting of the
particles to the titanium surface.
Dendrimers
Dendrimers are hyperbranched molecules discovered by Frtiz Vogtle in 1978. He named them ‘dendron,’ which
comes from a Greek word, meaning ‘tree.’ As the name suggests, dendrons are monodispersed macromolecules
that possess extremely forked 3D structures. They are capable of delivering not only hydrophobic drugs but also
hydrophilic drugs [88]. Dendrimers in general possess a ball-shaped structure containing a polymeric terminus
(exo-receptor). These NPs can demonstrate peculiar functionality through the confounded chemistry, differing in
their interior endoreceptor binding groups [89,90].
Fucose-specific lectins (Lec-B) are produced by P. aeruginosa during the formation of biofilm. Lec-B is integral
in the process of biofilm formation, and the mutants that have Lec-B deficiency show dysfunctional biofilm
formation that was further examined by Johansson et al., who studied Lec-B inhibition, specifically whether the
Lec-B inhibition with elevated affinity polyvalent fucosyl-peptide dendrimers interrupts the binding process and
stops the development of biofilm [91]. Johansson et al. used a combination library screening approach, allowing
them to find one particular ligand, FD2 (C-Fuc-LysProLeu)4 (LysPheLyslle)2 (LysHisIleNH)2, which was capable
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of completely suppressing P. aeruginosa biofilm formation and dispersing the already developed biofilm formed by
P. aeruginosa clinical isolates. The study reveals the captivating potential of dendrimers that show antimicrobial and
antibiofilm formation activities even in the absence of incorporated antibiotics or antimicrobials attached to the
surface of NPs.
Cyclodextrins
Cyclodextrins (CDs) have a hydrophobic interior due to the carbon skeletal structure of glucopyranose monomers
and a hydrophilic surface in a truncated cone-shaped structure. CDs are cyclic organic compounds that mainly
belong to glucopyranose units coupled with α-1,4-glycosidic linkage [92]. Despite the weak solubility of CD in water,
it has several applications because of its unique function as a solubilizer for compounds with weak water solvability.
In a recent study, it was found that CDs combined with nitric oxide (NO) were able to eradicate all biofilms by using
the same concentration of NO as given in the inhaled formulation [93]. The ability of NO-releasing cyclodextrins
against P. aeruginosa, which is the main contributor to morbidity and mortality in CF patients, suggests that NO
has the potential to become a superior antibiofilm treatment when combined with controlled-release NPs [93].
Chitosan nanoparticles
Chitosan, a polysaccharide molecule derived from chitin is one of the most abundant polymers found in nature.
The substance is made by (β)-1,4 d-glucosamine linked to N-acetyl-d-glucosamine residues [94]. It displays unique
properties, including biodegradability and biocompatibility, which make it a good choice for researchers. It is also
a cost-effective alternative for many uses in food safety and biomedicine [95]. Chitosan also possesses antibacterial
and anti-biofilm properties against S. aureus, E. coli, and S. typhimurium [96]. Chitosan NPs are formulated through
ion gelation with TPP (polyanionic sodium triphosphate) [97].
The efficiency of chitosan nanoparticles against S. mutans was reported [98]. Chitosan and its interactions with the
bacterial biofilm have been explained in several ways [99,100]. One of the proposed mechanisms describes interactions
between the positively charged chitosan molecules and the negatively charged microbial cell membranes, leading
to the leakage of proteinaceous and some other intracellular constituents [101,102]. Chitosan NPs can retain their
charge even at neutral pH. The other mechanism proposed is the binding of chitosan NPs with microbial DNA,
which interferes with the mRNA and protein synthesis in the bacterial cells of the biofilm after the bacteria enters
the cell.
The study of chitosan NPs against S. mutans biofilm revealed the antimicrobial activity of chitosan NPs, which are
efficient at pH 7. Chitosan NPs with a lower molecular weight show a stronger trend toward higher particle activity.
In addition, the chitosan NPs with a lower molecular weight may affect the cohesion of the cell membrane of S.
mutans in a homogenous fashion throughout the entire biofilm. Given the successful results of this study, it may be
concluded that the system could be improved even further with uniform delivery of chitosan NPs at a neutral pH
throughout the biofilms. It is modified by combining it with other compounds. Chitosan NPs may aid in targeting
highly potent and variable microorganisms in a complex biofilm system if modified with suitable compounds [98].
Inorganic NPs
Silver NP formulations
Silver NPs (AgNPs) are acclaimed for their prominent antimicrobial activity. Silver NPs are used against the biofilms
of S. epidermidis and P. aeruginosa [103].
Silver NPs can be prepared by several methods [104]. AgNPs are reported to successfully inhibit the growth and
biofilm formation of both Gram-negative and Gram-positive bacterial strains, even at a very low concentration,
compared with the minimum inhibitory concentration breakpoints of other antibiotics. Furthermore, AgNPs
displayed no reduction or cytotoxicity against mammalian cells [105].
Another study also reported that P. aeruginosa PAO1 biofilms were inhibited by treatment with silver NPs [106].
The purpose of this study was first to determine the potency and effectiveness of the citrate-capped AgNPs of
various dimensions alone and, second, AgNPs amalgam with monobactam antibiotics, aztreonam to inhibit the
targeted biofilm. The findings suggested that potentially smaller dimension AgNPs enhanced the antimicrobial
effects of aztreonam against P. aeruginosa in vitro, revealing a potential role for amalgams of smaller size AgNPs
with antibiotics in the treatments of patients with chronic pulmonary infections and diseases. Therefore, the role
of silver NPs in chronic respiratory infection treatment has much potential for further research.
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Gold NPs
A recently reported study discussed the use of phosphatidylcholine-coated gold NPs packed with gentamicin (GPA-
NPs) [107]. The GPA-NPs had a size of 180 nm, and a uniform size of NPs was used. The findings revealed that
the GPA-NPs sustain their antibiotic mechanisms against planktonic bacteria, compelling to impair the settled
biofilms. The results revealed the successful inhibition of biofilm formation of both Gram-negative and Gram-
positive pathogenic bacteria. Moreover, the GPA-NPs also displayed a nontoxic trait in RAW264.7 cells. Therefore,
it may be concluded that GPA-NPs might play a crucial role as a potential antimicrobial agent with promising and
effective treatment of chronic pulmonary infections due to intracellular bacteria and microbial biofilms.
Recent research has cast light on the biofilm-inhibiting property and bactericidal activity of such NPs on S.
aureus and P. aeruginosa [108]. By reducing the surface charge of AuNPs, cell toxicity was decreased. The in vitro
studies on AuNPs propose that the modulations of the surface charge of AuNP may be exercised to stabilize the
effects on bacteria against airway cells in ventilator-associated pneumonia (VAP).
Silica NPs
Some pathogenic strains of bacteria have the potential to withstand antibiotics. This has led to the search for
novel approaches against microbial resistance and potential therapies against the development of infectious biofilms
in patients with pulmonary infections. Silica NPs (SiNPs) are a good option to deliver drugs, such as antibiotics
against biofilms and to show therapeutic inhibition and antimicrobial effects in chronic infections.
Pinto et al. reported on NO-encapsulated SiNPs to target biofilms of S. aureus and P. aeruginosa [109]. In this study,
NO showed antimicrobial activity and cell death. With an increased aspect ratio and reduced nanoparticle size,
NO-SiNPs were considerably effective against both biofilms of S. aureus and P. aeruginosa, whereas the Gram-
negative species exhibited higher sensitivity to NO. The conclusions also stated that the smaller the size of NP
formulations, the greater the efficacy of the NO antimicrobial properties and better delivery. The shape of the NP
was another factor in improving the function of NO. The rod shape of SiNPs showed a better delivery than normal
circular SiNPs.
Conclusion
It is estimated that approximately 60% of chronic or recurrent infections have a direct link to biofilms. Therefore, to
treat biofilm-associated respiratory infections, several extensive studies have been ongoing across the globe. Several
potent drug molecules have been studied and suggested to inhibit multiresistant biofilms and to suppress their
actions. Two of the effective strategies, inhaled formulations and nanoparticles, were discussed in detail in this
review.
A significant feature of NP delivery is the size range of the particles administered, which are <1 μm in size,
compared with many other drug-delivery techniques which have particles <5 μm in size. Furthermore, NPs
uniformly distribute the targeted drug in alveolar regions, which could improve drug targeting in the lungs. This
has also been shown to increase the surface area of the drug per unit mass and maximize the accumulation of the
drug in the lungs.
Apart from such drug-delivery techniques, another effective way of managing respiratory infections is by providing
inhaled formulations as treatment modalities. Inhaled formulations may target biofilms that cause respiratory
infections. In addition to the parenteral and oral delivery techniques, inhaled formulations may be used in
combination, which could prove promising in the near future. The use of NPs holds huge potential, and NO-
containing NP formulations were found to be the most promising and suitable for therapeutic use.
Future perspective
Biofilm infections are common and clinically significant, resulting in potentially fatal infections. However, our
understanding of their role in chronic pulmonary infections is still limited. The emerging evidence also implies that
biofilms are not just limited to bacteria but also extend to other infections such as those produced by mycobacteria
and H. influenzae. The treatment of biofilm infections is hindered by several potential challenges, as discussed in
detail in this review. These factors limit the applications of current antibacterial and antifungal drugs. Nevertheless,
the application of nanotechnology seems to provide some interesting evidence as a potential treatment modality
in the treatment of various biofilm-associated infections in chronic respiratory diseases. This novel approach holds
promising in vitro and in vivo potential. However, there is still an urgent need for in-depth mechanistic and
translation-oriented studies before such advanced strategies can be used in regular clinical practice.
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Executive summary
Biofilms: Multiresistant properties & prevention
Multidrug resistant properties in biofilms
• Exopolysaccharides provide delay in the penetration of antimicrobial drugs and are one of many contributing
factors to multidrug resistance.
Heterogeneity
• The bacterial cell culture shows a period of slow or no growth during limited supply of nutrition, and this
transition is suggested to be a critical factor leading to antibiotic resistance.
Prevention of biofilms
Various types of biofilms in respiratory infection
• Pseudomonas aeruginosa, Aspergillus fumigatus, Mycobacterium abscessus, Haemophilus influenzae,
Streptococcus pneumoniae and Staphylococcus spp. are predominantly seen in respiratory infections that form
biofilms.
Diagnosis of biofilms
• Biofilm infections are complex to diagnose by conventional methods of sampling or through microbiology tests.
• Biofilm infections could also relapse or fail to respond to antimicrobial therapies.
Challenges in treatment strategies
• The current methods of treatment for biofilm infections are not efficient and face many complicated hurdles for
microbiologists and clinicians.
• Multidrug resistance and varied metabolic activity pose as a challenge in biofilm treatment.
Current methods of treatment
Antibiotic treatment (high concentrations) administered through topical route
• Antibiotic treatment, if used as a sole method to treat biofilm infection, might not yield the best results.
Combined & sequential antimicrobial therapies
• Biofilm infection treatment will require the collaboration of other therapies, including clinical microbiology,
surgery, internal medicine and basic and clinical pharmacology.
• Understanding the nature of microbial biofilms will help in determining the combined and sequential therapies
against it.
Inhaled antimicrobial formulations: treatment of biofilm-induced respiratory infections
• Inhaled formulations have relatively shown positive outcomes in vitro. However, they were not successful in their
ability to reach the site of action in vivo.
Quorum sensing (QS) inhibitors & anti-QS peptides to control biofilm infection
• It has been suggested that the current biofilm treatments should use strategies to penetrate biofilms. In addition,
it is suggested that sensitive antibiotics combined with high-dose antibiotics be employed along with QS
treatment to successfully disperse and kill microbes in a biofilm.
Antagonists of diguanylate cyclase (DGC)
• The use of inhibiting compounds of DGC showed damage to P. aeruginosa and Acinetobacter baumannii biofilms.
Bacteriophage therapies
• Bacteriophage therapies were able to show positive results in implant-, biofilm-related infections and





• The liposome-based nanoparticles (NPs) when loaded with linezolid against methicillin-resistant Staphylococcus
aureus (MRSA) have showed potential antibiofilm activity. The liposomal NPs might be efficient against
osteomyelitis causing MRSA, which is difficult to treat.
Solid lipid nanoparticles
• The solid lipid NPs are utilized specifically to target the developing biofilms rather than developed biofilms.
Microemulsions
• Microemulsions loaded with curcumin was successfully employed against planktonic Staphylococcus mutans,
Lactobacillus casei, Actinomyces viscosus and Candida albicans. The findings revealed that microemulsion-loaded
formulation was better in yielding more promising results against microorganisms.
• Microemulsions have the potential to be used as therapeutic agent alone or as a drug carrier.
Polymeric-delivery system
Dendrimers
• Lec-B, an essential agent required for biofilm growth, is inhibited by polyvalent fucosyl-peptide dendrimers.
• Studies have revealed the captivating potential of dendrimers that show antimicrobial and antibiofilm formation
activity, even in the absence of incorporated antibiotics or antimicrobials attached to the surface of NPs.
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Cyclodextrins
• Nitric oxide (NO)-releasing cyclodextrins have shown promising results in recent studies in completely eradicating
the P. aeruginosa biofilm in patients.
• Cyclodextrins may become efficient candidates for research against antibacterial biofilm in respiratory diseases.
Inorganic delivery system
Gold NPs
• Gold NPs have shown potent antimicrobial activity against S. aureus and P. aeruginosa.
• Toxicity could be reduced in Gold NPs by reducing the surface charge.
Silver NPs
• Silver NPs have shown successful antimicrobial activity against S. epidermidis and P. aeruginosa biofilms.
• They can be used at a very low concentration and do not result in cytotoxicity in mammalian cells.
Silica NPs
• NO-silica NPs (siNPs) were considerably productive against both biofilms of S. aureus and P. aeruginosa, whereas
the Gram-negative species exhibited higher sensitivity to NO.
• The rod-shaped SiNPs showed better delivery than normal circular-shaped SiNPs.
Chitosan NPs
• Chitosan NPs, when used with phosphatidylcholine and gentamicin, were able to improve the penetration of
drugs into the biofilm and engulfment of NPs by macrophages with a negligible cytotoxicity to cells.
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